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Edited by Lukas HuberAbstract Plasma membrane Ca2þ-ATPase is involved in the
ﬁne-tuned regulation of intracellular Ca2þ. In this study, the
presence of Ca2þ-ATPase in caveolae from kidney basolateral
membranes was investigated. With the use of a discontinuous
sucrose gradient, we show that Ca2þ-ATPase is exclusively
located and fully active in caveolin-containing microdomains.
Treatment with methyl-b-cyclodextrin – a cholesterol chelator –
leads to a spreading of both caveolin and completely inactive
Ca2þ-ATPase toward high-density fractions. These data support
the view that Ca2þ ﬂuxes mediated by Ca2þ-ATPase in kidney
epithelial cells occur only in caveolae, being strictly dependent on
the integrity of these microdomains.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The main parts of the regulatory system involved in cell
calcium homeostasis are the diﬀerent sets of transport that are
present either in the membranes of internal stores as
sarco(endo)plasmic reticulum, which is driven through diﬀer-
ent sarco(endo)plasmic reticulum Ca2þ-ATPases [1], or in the
plasma membrane, where it is driven through the Naþ–Ca2þ
exchanger and the plasma membrane Ca2þ-ATPase [2–7].
Since it was ﬁrst reported by Yamada [8], rapid growth in
caveolae research has brought major advances in under-
standing its structure, as well as the development of methods
for purifying and characterizing its composition. These studies
were carried out in many diﬀerent cell types, where these
plasma membrane microdomains were detected [9–11]. How-
ever, there are some reports that argue whether caveolae are
really involved in the functions attributed to them (for example
see [12]).
Quantitative analyses by immunoﬂuorescence and immun-
ocitochemistry of endothelial cells, smooth muscle cells, car-* Corresponding author. Fax: +55-21-2280-8193.
E-mail address: avieyra@biof.ufrj.br (A. Vieyra).
Abbreviations: BLM, basolateral membranes; MbCD, methyl-b-cyclo-
dextrin; Polidocanol, polyoxyethylene 9 lauryl ether
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and capillary endothelial cells have shown that Ca2þ-ATPase
was found to be concentrated 18–25-fold in the caveolar
membrane compared with the non-caveolar portion of the
plasma membrane [13,14]. However, there are no biochemical
data reporting the activity of Ca2þ-ATPase in its caveolar lo-
calization. The caveolar localization of the Ca2þ pump appears
to be crucial for kidney function, even though the ﬁrst studies
on caveolae have demonstrated that these microdomains are
not abundant in kidney tubules [13]. It was shown that the
knock out of the caveolin-1 gene promotes the progressive
steps required for urinary calcium lithiasis [15]. Moreover, it
was observed that the dysfunction of caveolin- and cholesterol-
rich microdomains is directly correlated and potentially in-
volved in the induction and maintenance phases of ischaemic
and toxic forms of experimental renal failure [16], emphasizing
the great importance of these specialized plasma membrane
microdomains in renal physiology and pathology. These ob-
servations led us to investigate whether the Ca2þ-ATPase
resident in the basolateral membranes (BLM) of proximal
tubule cells is active in its caveolar localization and also to
compare the Ca2þ-ATPase activity from caveolar and non-
caveolar fractions in the above kidney segment. In this tubule
segment more than 70% of the glomerular ﬁltrate is recovered
for the body liquid compartments, and reabsorption of ﬂuid
appears to be highly sensitive to the cytosolic Ca2þ ﬂuctuations
[17] which are controlled in part by the BLM Ca2þ pump [18].2. Materials and methods
2.1. Materials
All the reagents used for isolation of the membranes, sucrose gra-
dient, Ca2þ-ATPase activity and protein determination as well as bo-
vine brain calmodulin, were from Sigma Chemical Co. (St. Louis,
MO). The reagents used for SDS–PAGE and Western blotting
(ECLTM and HyperﬁlmTM) were from Amersham (Buckinghamshire,
UK). The monocolonal antibody anti-PMCA (5F10) and the poly-
clonal antibody anti-caveolin-1 (anti-cav-1) were from Aﬃnity BioR-
eagents (Golden, CO) and Santa Cruz Biotechnology Inc. (Santa Cruz,
CA), respectively.
2.2. Isolation of BLM
BLMs from pig kidney proximal tubule cells were isolated and pu-
riﬁed using the Percoll gradient method [19] and stored in 250 mM
sucrose under liquid N2 at a ﬁnal protein concentration of 30–35 mg/
ml. Under these conditions, Ca2þ-ATPase activity is preserved for atation of European Biochemical Societies.
Fig. 1. Association between caveolin and full active Ca2þ-ATPase activity in plasma membranes from kidney tubule cells. Representative Western
blot of caveolin (25 kDa) polyclonal antibody anti-cav-1 (1:1000) in membrane fractions separated in a polidocanol-containing discontinuous sucrose
gradient after centrifugation for 16 h [repeated ﬁve times with diﬀerent preparations] (A). Representative Western blot of Ca2þ-ATPase using
monoclonal antibody anti-PMCA, 5F10 clone (1:1000), in the same gradient (B). Ca2þ-ATPase activity in the fractions indicated on the abscissa (C).
The Ca2þ-ATPase activity control value from diﬀerent BLM preparations, incubated at 4 C without centrifugation for 16 h, was 10 2
nmol Pimg1min1 (n ¼ 5).
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brane fragments [19]. Protein determination was carried out by the
Folin-phenol method [20], using bovine albumin as standard. The
speciﬁc activity of the BLM marker (Naþ–Kþ)ATPase was 15-fold
enriched when compared to the initial kidney cortex-corticis homog-
enate. Diﬀerent preparations selected at random showed that residual
contamination with subcellular membrane markers was minimal [21].
2.3. Caveolae fractionation
BLM-enriched fractions obtained as described above were treated
with polidocanol (1%, v/v). This material was sonicated three times
(10 s each) and then fractionated in a discontinuous sucrose gradient
(5–45%), as previously described [22]. The 12 top to bottom fractions
obtained (1 ml each) were used for Western blotting assays and de-
termination of Ca2þ-ATPase activity.
2.4. Ca2þ-ATPase activity determination
Ca2þ-ATPase activity was measured using the colorimetric method
described by Taussky and Shorr [23]. The native BLM fraction or the
diﬀerent sucrose gradient fractions were incubated in the following
reaction medium (1 ml): 50 mM bis-Tris propane–HCl (pH 7.4), 10
mM NaN3, 1 mM ouabain, 120 mM KCl, 5 mM MgCl2, 0.2 mM
EGTA and 0.27 mM CaCl2 (20 lM free Ca2þ). The reaction was
started by adding 5 mM ATP to the reaction medium. After 20 min at
37 C the reaction was stopped with two volumes of a cold activated
charcoal suspension in 0.1 N HCl. An aliquot of the supernatant ob-
tained after centrifugation (600 g, 40 min) was used for the colori-
metric assay. Spontaneous Pi release was measured in tubes run in
parallel in which the membranes were added after the charcoal. The
Ca2þ-ATPase activity was measured by the diﬀerence of the ATP
hydrolysis in the presence and absence (0.2 mM EGTA) of CaCl2. Free
Ca2þ concentration was calculated using a computer program that
took into account the diﬀerent species involved in the equilibrium
between EGTA, Ca2þ, ATP, Mg2þ, Hþ and Kþ, and the inﬂuence of
ionic strength on the association constant for the Ca–EGTA complex
[24,25].
2.5. Preparation of calmodulin-depleted membranes
Calmodulin-depleted BLM were obtained after incubation of the
membranes in mild alkaline (pH 7.8) hypotonic (10 mM Tris–HCl, 2
mM EDTA) buﬀer according to Niggli et al. [26] with slight modiﬁ-
cations [27].2.6. Preparation of cholesterol–cyclodextrin inclusion complex
The inclusion complex of cholesterol and MbCD was prepared ac-
cording to Klein et al. [28] with slight modiﬁcations. Brieﬂy a solution
of MbCD in water (0.2 M) was supplied with cholesterol under con-
tinuous stirring at room temperature. When the dextrin was fully
loaded with cholesterol (cholesterol–MbCD molar ratio 1.8:1), an al-
iquot of the clear solution containing the complex was added to the
Ca2þ-ATPase assay to give a ﬁnal concentration of 75 mg/ml.
2.7. Electrophoresis and Western blotting
After sodium dodecylsulfate–polyacrylamide gel electrophoresis
(15% acrylamide) of the BLM [29], proteins were transferred to a ni-
trocellulose membrane and incubated with the desired antibodies (see
legend to the ﬁgures for the dilutions). After four washes in TBS-T (5
min each), the membranes were incubated for 1 h at room temperature
with an anti-rabbit peroxidase conjugate antibody (dilution 1:5000 in
TBS-T solution). The membranes were washed again as described
above, and the bands were visualized using the ECL system kit.3. Results and discussion
3.1. Localization of the Ca2þ pump from BLM in caveolin-rich
fractions
With the use of a policlonal antibody against caveolin-1,
we detected a clear signal of abundant caveolin – and
therefore caveolae – in BLM derived from kidney proximal
tubule cells. Fig. 1A shows that caveolin is only found in the
low density, cholesterol-rich fractions of the sucrose gradient
(fractions 3–6) [9,30]. These fractions are the same as those in
which Ca2þ-ATPase was detected by the monoclonal anti-
body anti-plasma membrane Ca2þ-ATPase (5f10), as shown
in Fig. 1B (fractions 3–6). In addition, the Ca2þ-ATPase
activity is found exclusively in the same fractions in which
caveolin-1 and plasma membrane Ca2þ-ATPase are detected
by the corresponding antibodies (Fig. 1C). These data clearly
show that Ca2þ-ATPase is compartmentalized and functional
only in caveolae.
Fig. 3. Inﬂuence of MbCD on Ca2þ-ATPase from calmodulin-depleted
membranes. Main panel: Ca2þ-ATPase activity was measured in the
conditions shown on the abscissa. CCM: calmodulin-containing
membranes; AHT: alkaline hypotonic treatement (see Section 2). Inset:
Ca2þ-ATPase activity measured in calmodulin-containing membranes
(CCM), in calmodulin-depleted membranes (CDM), and in mem-
branes ﬁrst depleted from their endogenous calmodulin by alkaline
hypotonic treatment and then supplied with 50 nM bovine brain
calmodulin.
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Ca2þ-ATPase
To clarify whether Ca2þ-ATPase really depends on the
integrity of caveolae to work, we carried out experiments
where the BLMs were pre-incubated, prior to fractionation in
the sucrose gradient, with MbCD, a well-known caveolae
disrupter due to its action in sequestering cholesterol. Many
studies have shown that cholesterol is a molecule critically
involved in caveolae stability and function [11,31,32] since
this membrane microdomain is highly sensitive to cholesterol
depletion [22,31]. Fig. 2A clearly shows that pre-treatment of
the BLM with MbCD promotes disruption of caveolae as
judged by the spread of caveolin detection along the entire
gradient, with a marked increase in the high-density regions
(fractions 10–12). It has been shown that after cholesterol
depletion by MbCD, the caveolin-containing complexes lose
their low-density property [31,33]. Therefore, it is expected
that, in the presence of MbCD, complexes of caveolin with
cytoskeleton proteins should also be present in the high-
density regions of the gradient [33] as shown in Fig. 2A.
Plasma membrane Ca2þ-ATPase was also distributed along
the entire gradient as revealed by its broader detection in the
Western blotting (Fig. 2B). When these fractions were as-
sayed for Ca2þ-ATPase activity, we were not able to detect
any functional pool of Ca2þ-ATPase (main panel in Fig. 2C),
thus suggesting that the caveolae microenvironment is strictly
necessary for Ca2þ-ATPase function in the BLMs of kidney
cells. Cholesterol depletion by MbCD also critically impairs
Ca2þ-ATPase activity when native membrane preparations
are used, instead of the solubilized preparation employed inFig. 2. Correlation between disruption of caveolae and inactivation of Ca2þ-A
treated with 50 mM MbCD (A). Western blot of fractions using antibody a
antibodies were as in legend to Fig. 1(B). Ca2þ-ATPase activity in memb
containing sucrose gradient (with 50 mM MbCD); inset, native membranes
concentrations or 75 mg/ml of cholesterol–MbCD complex (1.8:1 molar ratio
ﬁve diﬀerent experiments carried out in triplicate.the gradient shown in the main panel of Fig. 2C. The inset to
Fig. 2C shows the concentration-dependent inhibition by
MbCD of the Ca2þ-ATPase activity of intact BLM. It is of
interest to mention that the (Naþ +Kþ)ATPase of these
membranes is also abolished by 50 mM MbCD (data not
shown).TPase. Representative Western blot of caveolin in membrane fractions
gainst Ca2þ-ATPase. The speciﬁc dilutions of the anti-cav-1 and 5F10
ranes treated with MbCD (C); main panel, fractions of polidocanol-
assayed for Ca2þ-ATPase activity in the presence of diﬀerent MbCD
), as shown on the abscissa. Results are presented as meansSEM of
Fig. 4. Model for the ﬁne-tuned regulation of cellular Ca2þ mediated by caveolar Ca2þ-ATPase after Ca2þ entry through the IP3 receptor-like protein
(IP3RLP) (see also [43]). The pathways for passive Ca
2þ entry and active Ca2þ eﬄux localized in close vicinity in caveolar microdomains would
warrant the ﬁne-tuned control of the intensity and duration of Ca2þ spikes and Ca2þ waves [43].
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[28,34] instead of free MbCD was used, there is no inhibition
of Ca2þ-ATPase activity. This indicates that cholesterol ex-
traction from the membranes – and not other non-speciﬁc
eﬀects – leads to loss of Ca2þ-ATPase activity, as is also the
case for membrane receptors [28] and molecular signaling
turnover [34]. However, when cholesterol was ﬁrst removed by
MbCD and caveolae were disrupted (Fig. 2A), incubation with
the inclusion complex – which is believed to be a cholesterol
donor [22,35] – is not enough to restore Ca2þ-ATPase activity.
Thus, we propose that cholesterol has two eﬀects on renal
Ca2þ-ATPase. One would be to preserve the caveolar integrity
needed for the stabilization and full activity of the pump. The
second eﬀect of cholesterol would be to contribute to the or-
ganization of an appropriate lipidic environment around the
renal Ca2þ-ATPase molecules as it is the case for the
(Naþ +Kþ)ATPase. Cholesterol stimulates the activity of
the Naþ pump in reconstituted systems [36,37] and this eﬀect is
not solely due to an increase in the hydrophobic thickness.
Rather, speciﬁc interactions between (Naþ +Kþ)ATPase
molecules leading to oligomerization and activation of the
pump could be favored by cholesterol [37]. This could be also
true for PMCA, which is also activated by oligomerization
[38]. It should be mentioned that the basal Mg2þ-stimulated,
Ca2þ-independent ATPase activity (2 mM EGTA) remains
unchanged after MbCD treatment, indicating that disruption
of caveolae by cholesterol removal speciﬁcally aﬀects the Ca2þ
pump.
3.3. Calmodulin depletion increases sensitivity to caveolar
disruption
Ca2þ-ATPase is the only ion pump stimulated directly by
calmodulin [2–7,26]. Thus, the next experiment addressed the
question of whether calmodulin modiﬁes inhibition of the
pump by MbCD. Fig. 3 shows that inhibition is more pro-
nounced when the membranes are depleted from their en-
dogenous calmodulin by alkaline hypotonic treatment. This is
an evidence that long-range intramolecular modiﬁcations of
the domains embedded in the membrane moiety – which are
induced by calmodulin binding at its cytosolic sites [6] –decrease the sensitivity of the pump toward cholesterol re-
moval and caveolar disarrangements.
3.4. Conclusions
As pointed out above, Ca2þ-ATPase is the molecular ma-
chine involved in the ﬁne-tuned regulation of cytosolic Ca2þ
activity. Its caveolar localization could facilitate its interaction
with modulators [39–41] and, especially, its cross-talk with the
main channel structure associated with Ca2þ entry, the IP3
receptor-like protein (IP3RLP) [42,43]. Fig. 4 illustrates our
proposal of a cross-talk between neighboring IP3RLP and
Ca2þ-ATPase, playing respective key roles in the induction and
termination of Ca2þ signals in the cells. The high aﬃnity of
caveolin for cholesterol [44] would be responsible for caveolar
oligomerization and stabilization, as well as for the proper
packaging of Ca2þ-ATPase and IP3RLP in the caveolar envi-
ronment. Thus, the data presented here are in line with the
view that alterations in cholesterol localization and caveolin
expression in speciﬁc membrane microdomains, impair Ca2þ
pumping activity and disrupt intracellular Ca2þ homeostasis
and signaling. The Ca2þ-elicited events turned on by caveolar
dysfunction might sustain activation of a myriad of cellular
cascades and trigger several uncontrolled pathological pro-
cesses [11,15,16,45].
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